An In-Depth Analysis of Original Antigenic Sin in Dengue Virus Infection

ABSTRACT The evolution of dengue viruses has resulted in four antigenically similar yet distinct serotypes. Infection with one serotype likely elicits lifelong immunity to that serotype, but generally not against the other three. Secondary or sequential infections are common, as multiple viral serotypes frequently cocirculate. Dengue infection, although frequently mild, can lead to dengue hemorrhagic fever (DHF) which can be life threatening. DHF is more common in secondary dengue infections, implying a role for the adaptive immune response in the disease. There is currently much effort toward the design and implementation of a dengue vaccine but these efforts are made more difficult by the challenge of inducing durable neutralizing immunity to all four viruses. Domain 3 of the dengue virus envelope protein (ED3) has been suggested as one such candidate because it contains neutralizing epitopes and it was originally thought that relatively few cross-reactive antibodies are directed to this domain. In this study, we performed a detailed analysis of the anti-ED3 response in a cohort of patients suffering either primary or secondary dengue infections. The results show dramatic evidence of original antigenic sin in secondary infections both in terms of binding and enhancement activity. This has important implications for dengue vaccine design because heterologous boosting is likely to maintain the immunological footprint of the first vaccination. On the basis of these findings, we propose a simple in vitro enzyme-linked immunosorbent assay (ELISA) to diagnose the original dengue infection in secondary dengue cases.

[1]  B. Rouse Faculty Opinions recommendation of Strategies to alleviate original antigenic sin responses to influenza viruses. , 2012 .

[2]  C. Midgley,et al.  An In-Depth Analysis of Original Antigenic Sin in Dengue Virus Infection , 2011, Journal of Virology.

[3]  Soila Sukupolvi-Petty,et al.  Genotype-Specific Neutralization and Protection by Antibodies against Dengue Virus Type 3 , 2010, Journal of Virology.

[4]  R. Rico-Hesse,et al.  Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2 , 2010, Journal of Virology.

[5]  C. Nelson,et al.  The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 , 2010, PLoS pathogens.

[6]  Ralph S. Baric,et al.  Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses , 2010, PLoS pathogens.

[7]  M. Diamond,et al.  Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification , 2010, PLoS pathogens.

[8]  D. Webster,et al.  Progress towards a dengue vaccine. , 2009, The Lancet. Infectious diseases.

[9]  R. Jarman,et al.  A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model , 2009, PLoS medicine.

[10]  M. Accavitti-Loper,et al.  Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. , 2009, Virology.

[11]  Soila Sukupolvi-Petty,et al.  On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. , 2009, The Journal of general virology.

[12]  G. Chang,et al.  Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens , 2009, PloS one.

[13]  Gregory D. Gromowski,et al.  Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. , 2009, Virology.

[14]  M. Guzmán,et al.  Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. , 2008, Virus research.

[15]  G. Chinea,et al.  Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells. , 2008, Virus research.

[16]  Gregory D. Gromowski,et al.  Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus , 2008, Journal of Virology.

[17]  Patrick C. Wilson,et al.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus , 2008, Nature.

[18]  G. Chang,et al.  Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II , 2008, Journal of Virology.

[19]  J. Roehrig,et al.  Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins , 2008, Nature Structural &Molecular Biology.

[20]  M. Guzmán,et al.  Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins , 2008, Archives of Virology.

[21]  Gregory D. Gromowski,et al.  Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. , 2007, Virology.

[22]  Gregory D. Gromowski,et al.  Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes , 2007, Journal of Virology.

[23]  J. Farrar,et al.  Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. , 2007, The Journal of infectious diseases.

[24]  Gregory D. Gromowski,et al.  Solution structure of the envelope protein domain III of dengue-4 virus. , 2007, Virology.

[25]  B. Murphy,et al.  Prospects for a dengue virus vaccine , 2007, Nature Reviews Microbiology.

[26]  M. St. Claire,et al.  Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention , 2007, Proceedings of the National Academy of Sciences.

[27]  Susana Vázquez,et al.  Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. , 2006, The American journal of tropical medicine and hygiene.

[28]  S. Green,et al.  Immunopathological mechanisms in dengue and dengue hemorrhagic fever , 2006, Current opinion in infectious diseases.

[29]  G. Nybakken,et al.  West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody , 2006, Proceedings of the National Academy of Sciences.

[30]  E. Konishi,et al.  Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. , 2006, Vaccine.

[31]  Chris Doane,et al.  Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus , 2005, Nature Medicine.

[32]  G. Air,et al.  Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. , 2005, Vaccine.

[33]  Y. Modis,et al.  Variable Surface Epitopes in the Crystal Structure of Dengue Virus Type 3 Envelope Glycoprotein , 2005, Journal of Virology.

[34]  Alan L Rothman,et al.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. , 2004, The Journal of infectious diseases.

[35]  Wen Chang,et al.  An External Loop Region of Domain III of Dengue Virus Type 2 Envelope Protein Is Involved in Serotype-Specific Binding to Mosquito but Not Mammalian Cells , 2004, Journal of Virology.

[36]  Tao Dong,et al.  Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever , 2003, Nature Medicine.

[37]  Y. Modis,et al.  A ligand-binding pocket in the dengue virus envelope glycoprotein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Schilling,et al.  Serological Differentiation of Infections with Dengue Virus Serotypes 1 to 4 by Using Recombinant Antigens , 2002, Journal of Clinical Microbiology.

[39]  J. H. Strauss,et al.  Structure of dengue virus: implications for flavivirus organization, maturation, and fusion , 2002 .

[40]  D. Gubler The global emergence/resurgence of arboviral diseases as public health problems. , 2002, Archives of medical research.

[41]  J. Roehrig,et al.  Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells , 2001, Journal of Virology.

[42]  G. Murphy,et al.  Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. , 2001, The American journal of tropical medicine and hygiene.

[43]  H. Bedouelle,et al.  Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. , 2001, The Journal of general virology.

[44]  J. Roehrig,et al.  Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. , 1998, Virology.

[45]  C. Hayes,et al.  Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. , 1998, The American journal of tropical medicine and hygiene.

[46]  S. Yoksan,et al.  The micro-focus reduction neutralization test for determining dengue and Japanese encephalitis neutralizing antibodies in volunteers vaccinated against dengue. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[47]  C. Lai,et al.  Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. , 1996, Virology.

[48]  S. Nitayaphan,et al.  Rapid detection and identification of dengue viruses by polymerase chain reaction (PCR). , 1996, The Southeast Asian journal of tropical medicine and public health.

[49]  C. Parrish,et al.  Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. , 1994, Virology.

[50]  R. Belshe,et al.  Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin". , 1994, The Journal of infectious diseases.

[51]  A. Nisalak,et al.  Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. , 1989, The American journal of tropical medicine and hygiene.

[52]  A. Nisalak,et al.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. , 1988, The American journal of tropical medicine and hygiene.

[53]  B. M. Kaufman,et al.  Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. , 1987, The American journal of tropical medicine and hygiene.

[54]  J. Blok Genetic relationships of the dengue virus serotypes. , 1985, The Journal of general virology.

[55]  S J Leach,et al.  Original antigenic sin: experiments with a defined antigen. , 1980, Molecular immunology.

[56]  S. Halstead In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. , 1979, The Journal of infectious diseases.

[57]  SB Halstead,et al.  Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody , 1977, The Journal of experimental medicine.

[58]  S. Halstead,et al.  Antibody-enhanced dengue virus infection in primate leukocytes , 1977, Nature.

[59]  A. Wilson,et al.  Immunological comparison of azurins of known amino acid sequence , 1975, Journal of Molecular Evolution.

[60]  S. Cohen,et al.  Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. , 1970, The Yale journal of biology and medicine.

[61]  R. Webster,et al.  DISQUISITIONS ON ORIGINAL ANTIGENIC SIN , 1966, The Journal of experimental medicine.

[62]  R. Webster,et al.  DISQUISITIONS ON ORIGINAL ANTIGENIC SIN , 1966, The Journal of experimental medicine.

[63]  R. Webster Original antigenic sin in ferrets: the response to sequential infections with influenza viruses. , 1966, Journal of immunology.

[64]  Thomas Francis,et al.  EPIDEMIOLOGIC AND IMMUNOLOGIC SIGNIFICANCE OF AGE DISTRIBUTION OF ANTIBODY TO ANTIGENIC VARIANTS OF INFLUENZA VIRUS , 1953, The Journal of experimental medicine.

[65]  Thomas Francis,et al.  INFLUENZA: THE NEWE ACQUAYANTANCE , 1953 .

[66]  A. Tokunaga,et al.  A Summary of , 2011 .

[67]  Gregory D. Gromowski,et al.  Short Communication Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III , 2010 .

[68]  J. Chin,et al.  The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. , 2007, Microbes and infection.

[69]  A. Nisalak,et al.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. , 2000, The Journal of infectious diseases.

[70]  R. Warren,et al.  Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. , 1995, Vaccine.

[71]  G. Kuno,et al.  Use of 'original antigenic sin' theory to determine the serotypes of previous dengue infections. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[72]  S. Halstead,et al.  Original antigenic sin in dengue. , 1983, The American journal of tropical medicine and hygiene.

[73]  T. Francis Influenza: the new acquayantance. , 1953, Annals of internal medicine.

[74]  A. Sabin Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.